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ABSTRACT
The reported incidence of grades II to IV acute graft-versus-host disease (GVHD) after hematopoietic cell
transplantation with HLA-identical sibling donors has increased considerably during the past 15 to 20 years at
our center. The purpose of this study was to evaluate the potential reasons for this change. We reviewed organ
stages and overall grades of GVHD for 2220 patients who received a first marrow or peripheral blood cell
transplant from an HLA-identical sibling or an HLA-allele-matched unrelated donor with the use of a
posttransplantation immunosuppressive regimen that included both methotrexate and cyclosporine between
1985 and 2001. The most striking change was an increased incidence of stage 1 gut involvement from 10% to
20% before 1992 to 50% to 60% since 1992, both with related and unrelated donors. This change increased
the incidence of grade II GVHD with sibling donors, such that the overall incidence of grade II to IV GVHD
is now 60% to 70%. Among patients with chronic myeloid leukemia in chronic phase, the increasingly frequent
diagnosis of acute GVHD since 1992 has not been associated with decreased survival. A high diagnostic
sensitivity and increased awareness that gut GVHD can occur without skin involvement account for the
increased incidence of acute GVHD at our center.
© 2004 American Society for Blood and Marrow Transplantation
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Despite more than 30 years of experience with
llogeneic hematopoietic cell transplantation (HCT),
he assessment of acute graft-versus-host disease
GVHD) still poses a difﬁcult challenge. Grading of
VHD can serve a variety of purposes, including
etrospective assessment of peak severity, real-time
valuation of severity at prespeciﬁed intervals, deter-
ination of the need for treatment, prognostication
or survival, and evaluation of new methods to prevent
VHD in prospective studies. The original criteria
or grading GVHD were formally proposed in 1974
1], and at least 2 modiﬁcations or reﬁnements have
een suggested and widely adopted since then [2,3]. v
20ne such modiﬁcation was the agreement at a con-
ensus conference that persistent nausea with histo-
ogic evidence of GVHD but no diarrhea should be
ncluded as stage 1 gut involvement [2]. It was also
ecommended that the nominal severity of liver or gut
VHD should be decreased by 1 stage when the
rgan was simultaneously affected by other complica-
ions, such as regimen-related toxicity or infection. A
urther reﬁnement evolved from a registry study that
uggested that correlations between peak GVHD
rade and transplant-related mortality could be im-
roved by assigning higher weight to the skin stage in
omputing the overall grade [3].
The assessment of GVHD severity necessarily in-
olves some level of subjective judgment both at the
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Bedside and in the interpretation of medical records.
e have previously questioned the reproducibility of
etrospective GVHD grading and have suggested 2
ifferent approaches for possible improvement, al-
hough neither approach has been demonstrably ac-
epted or endorsed in any center [4,5]. Our awareness
f the need for more robust methods of GVHD grad-
ng originated soon after 1991, when the task of as-
igning ﬁnal GVHD grades at out center passed from
reviewer to another. This change was accompanied
y an increase in overall GVHD grades, particularly
fter HCT with HLA-identical sibling donors. More-
ver, the incidence rates of acute GVHD reported for
atients who have had allogeneic HCT at our center
emain considerably higher than those observed else-
here, even when the same treatment protocols have
een used. The purpose of this study was to evaluate
otential reasons for the changes in GVHD incidence
cross 17 years at our center.
ATIENTS AND METHODS
tudy Population
This study included patients who received their
rst marrow or peripheral blood cell transplants from
LA-identical siblings (n  1754) or HLA-matched
nrelated donors (n  366) with the use of conven-
ional pretransplantation conditioning regimens and a
osttransplantation immunosuppressive regimen that
ncluded both methotrexate and cyclosporine [6-9].
ases were excluded if complete GVHD grades were
ot available. HLA typing was performed with the use
f serologic methods and DNA-based methods as pre-
able 1. Characteristics of the Study Population
Characteristic Siblings 1985-1991 (n
iagnosis, n (%)
Acute lymphoblastic leukemia 113 (13)
Acute myeloid leukemia 189 (22)
Chronic myeloid leukemia 320 (37)
Myelodysplastic syndrome 68 (8)
Non-Hodgkin lymphoma 64 (7)
Hodgkin disease 24 (3)
Myeloma 10 (1)
Other 72 (8)
edian age, y (range) 32 (0.3-65)
onor/recipient sex, n (%)
Male/male 273 (32)
Male/female 183 (21)
Female/male 212 (25)
Female/female 192 (22)
otal body irradiation, n (%) 652 (76)
ype of graft, n (%)
Marrow 860 (100)
Mobilized peripheral blood cells 0 (0)
Marrow and peripheral blood cells 0 (0)iously described [10]. Unrelated donor/recipient s
B&MTairs included in this study were identical for HLA-A,
B, -C, -DRB1, and -DQB1 alleles. Institutional re-
iew board approval was obtained to permit review of
database containing health information for identiﬁ-
ble subjects in this study. Characteristics of the study
opulation are summarized in Table 1.
ransplantation Protocols
Transplantation protocols have been previously
escribed [6,7,11-13]. Conditioning regimens typi-
ally included the use of high-dose cyclophosphamide
ogether with fractionated total body irradiation (TBI)
r high-dose busulfan. Trimethoprim and sulfame-
hoxazole were given for prevention of Pneumocystis
arinii pneumonia. Laminar airﬂow rooms and oral
onabsorbable antibiotics were used for some patients
ntil 1994. For patients in conventional hospital
ooms, systemic antibiotics were administered to pre-
ent bacterial infection when absolute neutrophil
ounts were less than 0.5  109/L. Acyclovir was
dministered to prevent herpes simplex virus reactiva-
ion in all seropositive recipients and was used before
990 to prevent cytomegalovirus (CMV) reactivation
n some seropositive recipients. Ganciclovir was ad-
inistered either at the time of initial engraftment or
reemptively at the ﬁrst evidence of infection to pre-
ent CMV disease in some CMV-seropositive patients
eginning in 1990 and in all such patients beginning
n 1991 [14,15]. Fluconazole was administered to pre-
ent fungal infection for some patients beginning in
990 and for all patients beginning in 1992 [16,17].
ntravenous immunoglobulin was administered to
) Siblings 1992-2001 (n  894) Unrelated (n  366)
68 (7) 43 (12)
215 (24) 60 (16)
305 (34) 261 (71)
131 (15) 1 (0.3)
49 (5) 0
9 (1) 0
39 (4) 0
78 (9) 1 (0.3)
42 (0.6-68) 37 (0.7-56)
287 (32) 144 (39)
181 (20) 94 (26)
240 (27) 61 (17)
186 (21) 67 (18)
324 (36) 356 (97)
625 (70) 345 (94)
263 (29) 21 (6)
6 (1) 0 860ome patients in randomized prospective trials from
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3986 to 1987 [18], from 1991 to 1993 [19], and from
995 to 1998.
VHD Grading
GVHD grades were assigned for all patients, re-
ardless of survival after the transplantation. Only 76
3.4%) of the 2220 patients in this study died before
ay 21. In assigning GVHD grades, reviewers used
esearch ﬁles containing copies of medical summaries
ritten by primary providers every month, biopsy
eports, correspondence with referring physicians, and
utopsy reports. Biopsies were performed for diagnos-
ic evaluation only in patients with symptoms. Medical
ummaries included paragraphs speciﬁcally describing
he use of medications for prophylaxis and treatment
f GVHD and discussions of any clinical manifesta-
ions of GVHD. Until 2000, the research charts in-
luded daily ﬂow sheets of information abstracted
rom the original medical records. These ﬂow sheets
ummarized the percentages of body surface involved
ith rash and the volumes of diarrhea. Beginning in
000, ﬂow sheets were replaced by summary informa-
ion describing the maximum extent of body surface
nvolved by rash and the maximum stool volume after
ay 21. Flow sheets and summary information both
rovided total serum bilirubin concentrations across
ime and indicated the presence of abdominal pain or
lood in stools, the presence of gut or liver complica-
ions other than GVHD, biopsy results, and adminis-
ration of immunosuppressive medications.
Reviewers followed patterns from the original Se-
ttle criteria in assigning GVHD grades [1]. Informa-
ion from biopsies was used to conﬁrm the diagnosis
f GVHD but was not used in the assignment of
VHD grades. J.E.S. was responsible for assigning
VHD grades until P.J.M. assumed this task in 199l.
.E.S. used clinical expertise in accounting for com-
lications other than GVHD in assigning the severity
f organ involvement, whereas P.J.M. adjusted organ
tages according to the convention endorsed by a
onsensus conference in 1994 [2]. Brieﬂy summarized,
rade 0 indicates the absence of clinical manifestations
f GVHD. Grade I GVHD indicates stage 1 or 2 skin
nvolvement (50% of body surface involved). Grade
I GVHD indicates stage 3 skin involvement (50%
ash) or adjusted stage 1 liver (bilirubin 2-3 mg/dL) or
ut (diarrhea with stool volume 1000 mL/d) in-
olvement. Beginning in 1992, isolated upper gastro-
ntestinal GVHD without diarrhea or rash was cate-
orized as stage 1 gut involvement and grade II
VHD overall [2]. Grade III GVHD indicates stage 4
kin involvement (bullae) or adjusted stage 2 to 4 liver
bilirubin 3.0 mg/dL) or gut (stool volume 1000
L/d) involvement, without GVHD as a major con-
ributory cause of death. Grade IV GVHD indicates
hat GVHD was a major contributory cause of death. b
22his categorization was intended primarily as a retro-
pective summary of GVHD severity and was not
esigned for use as a prognostic indicator of trans-
lant-related mortality [3].
ESULTS
ncidence of Overall GVHD Grades and Organ
tages across Time
The reported incidence rates of grade II to IV
VHD after HCT with HLA-identical sibling donors
ncreased from 25% to 45% between 1985 and 1990
o 60% to 75% after 1990 (Figure 1). Although there
ere some changes from year to year, the incidence of
rade III and IV GVHD did not show a consistent
rend across time, suggesting that the major change
cross time was an increase in the incidence of grade II
VHD. In comparison to the dramatically increased
ncidence of grade II to IV GVHD with HLA-iden-
ical sibling donors across time, the incidence of grade
I to IV GVHD with HLA-matched unrelated donors
howed only modest increases across time, with no
onsistent changes in the incidence of grade III and IV
VHD.
We examined GVHD stages in the skin, liver, and
ut to identify whether any individual organ ac-
ounted for the increased incidence of grade II to IV
VHD after HCT with HLA-identical sibling do-
ors. The incidence of stage 1 gut involvement in-
reased strikingly from 10% to 20% between 1985
nd 1991 to 40% to 55% after 1991, whereas the
ncidence of stage 2 to 4 gut involvement did not show
consistent trend across time (Figure 2). A similarly
triking increase in the incidence of stage 1 gut in-
olvement also occurred with HLA-matched unre-
ated donors, whereas the incidence of stage 2 to 4 gut
nvolvement seemed to decrease slightly. The distri-
igure 1. The incidence of grade II to IV GVHD (■) has increased
arkedly after HCT with HLA-identical sibling donors but less so
ith HLA-matched unrelated donors. The incidence of grade III to
V GVHD ({) did not show a similar increase in either population.
he number of patients with HLA-matched unrelated donors was
oo small to analyze at yearly intervals. For this reason, data were
nalyzed for transplantations during 1985 to 1989 and during 2-year
ntervals thereafter.ution of GVHD stages in the skin and liver showed
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Bo consistent trends across time with either related or
nrelated donors (data not shown).
ncidence of Gastrointestinal Biopsy and Patterns
f GVHD Manifestations among Patients with
rade II GVHD and Stage 1 Gut Involvement
From 1985 to l991, approximately 20% to 30% of
ll patients had endoscopic or rectal biopsy for diag-
ostic evaluation of gastrointestinal complications
uring the ﬁrst 100 days after HCT (Figure 3). Since
992, the incidence of endoscopic or rectal biopsy has
ncreased gradually to 50% to 60%. The increased use
f endoscopic or rectal biopsy could have facilitated
he diagnosis of gastrointestinal GVHD in the ab-
ence of cutaneous involvement. To test this hypoth-
sis, we separated patients who had stage 1 gut in-
olvement with or without stage 1 liver involvement
ut no skin involvement from those who had any
ther pattern of grade II GVHD. Results in Figure 4
how an increase in the incidence of stage 1 gut in-
olvement without skin involvement after HCT with
LA-identical sibling donors, beginning in 1992. The
esults also suggest a more gradual increase in the
ncidence of other patterns of grade II GVHD in this
roup.
We reviewed biopsy and treatment records of all
68 patients with stage 1 gut involvement and no skin
nvolvement after HCT from HLA-identical siblings
o conﬁrm the diagnosis. All but 7 (4%) had a gastro-
igure 2. The incidence of stage 1 gut GVHD (■) has increased
cross time. The incidence of stage 2 to 4 gut GVHD ({) did not
how similar changes.
igure 3. The proportion of patients who have endoscopic or rectal
iopsy for diagnostic evaluation of gastrointestinal complications
uring the ﬁrst 100 days after HCT has increased across time. w
B&MTntestinal biopsy, and all but 2 (1%) received treat-
ent for GVHD. All had either biopsy or treatment
or gastrointestinal GVHD. In addition, case records
ere reviewed to assess symptoms reported for pa-
ients who had stage 1 gut involvement without skin
VHD during 2000 or 2001. Among 44 such cases,
8 (41%) had upper gastrointestinal symptoms with-
ut diarrhea, whereas the remainder had diarrhea with
r without upper gastrointestinal symptoms.
We found a less striking increase in the incidence
f stage 1 gut involvement without skin involvement
fter HCT from HLA-matched unrelated donors
Figure 4), whereas the incidence of other patterns of
rade II GVHD showed no consistent trend across
ime. The incidence rates of stage 1 to 4 and 3 to 4
kin involvement were substantially higher with HLA-
atched unrelated donors than with HLA-identical
ibling donors (Figure 5). From 1992 to 2001, 86% of
atients with stage 1 gut involvement after HCT with
LA-matched unrelated donors also had skin involve-
ent, compared with 58% among patients with stage
gut involvement after HCT with HLA-matched
ibling donors.
se of Parenteral Nutrition
An increase in the true incidence of gastrointesti-
al GVHD across time should have caused increased
sed of parenteral nutrition after recovery from the
igure 4. The incidence of stage 1 gut GVHD without skin in-
olvement (■) has increased, particularly after HCT with HLA-
dentical sibling donors. Other patterns of grade II GVHD ({) have
hown less striking changes across time.
igure 5. Stage 1 to 4 (■) and 3 to 4 ({) skin GVHD occurred more
requently after HCT with HLA-matched unrelated donors than
ith HLA-identical sibling donors.
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3ffects of the conditioning regimen. Contrary to this
xpectation, the proportion of patients who received
arenteral nutrition beyond 3 weeks from the trans-
lantation decreased across time (Figure 6). Until
992, more than 90% of patients with HLA-identical
ibling donors required parenteral nutrition at some
ime after day 21, and until 1993, the same was true
or more than 98% of patients with HLA-matched
nrelated donors. Since then, the incidence of paren-
eral nutrition after day 21 has decreased to approxi-
ately 66% with HLA-identical sibling donors and to
pproximately 75% with HLA-matched unrelated do-
ors.
orrelation between GVHD Grade and Survival
mong Patients with Chronic Myeloid Leukemia in
hronic Phase
Because previous studies have used a correlation
etween the peak severity of acute GVHD and trans-
lant-related mortality to demonstrate the validity and
edical signiﬁcance of different GVHD grades
1,20,21], it was of interest to determine whether the
ncreasingly frequent diagnosis of GVHD since 1992
as associated with any change in transplant-related
ortality. For this purpose, we selected patients with
hronic myeloid leukemia (CML) in chronic phase at
he time of the transplantation. These patients are
articularly well suited for this analysis, because the
isks of transplant-related mortality from causes un-
elated to GVHD and the risks of recurrent malig-
ancy and death after the development of recurrent
alignancy are all low, thereby minimizing the con-
ounding effect of complications other than GVHD.
Table 2 shows the distribution of GVHD grades
or patients with CML in chronic phase who received
CT from HLA-identical siblings from 1985 to 1991
r from 1992 to 2001. As expected, the 1992 to 2001
ohort showed a striking decrease in the number of
atients with grade 0 GVHD and a corresponding
ncrease in the number with grade II GVHD. The
igure 6. Use of parenteral nutrition beyond day 21 after trans-
lantation has decreased across time. Results exclude 76 patients
ho died before day 21 and 16 patients for whom information was
issing.umber of patients with CML in chronic phase who
24eceived HCT from HLA-matched unrelated donors
rom 1985 to 1991 was too small for meaningful anal-
sis (n  35). The last column of Table 2 shows the
istribution of GVHD grades for patients with CML
n chronic phase who received HCT from HLA-
atched unrelated donors from 1992 to 2001. This
ohort had a substantially higher incidence of grade
II GVHD, with corresponding reductions in the in-
idence of grade 0 and I GVHD as compared with the
992 to 2001 cohort of patients with HLA-identical
ibling donors.
Within each cohort, the 1-year survival among
atients with grade 0, I, or II GVHD showed no
igniﬁcant differences (Table 3). In the 1985 to 1991
ohort, 1-year survival for patients with grade III
VHD was not signiﬁcantly lower than for those with
rade 0 to II GVHD. In both 1992 to 2001 cohorts,
owever, 1-year survival for patients with grade III
VHD was lower than for those with grade 0 to II
VHD (P  .005 for sibling recipients and .007 for
nrelated recipients; Wald test). All patients with
rade IV GVHD died within 1 year after transplan-
ation. The change in distribution between grade 0
nd grade II GVHD among patients with HLA-iden-
ical sibling donors in the 1992 to 2001 cohort com-
ared with the 1985 to 1991 cohort was not associated
ith a decrease in survival. In fact, 94% (95% conﬁ-
ence interval [CI], 90%-97%) of patients with grade
to II GVHD survived for 1 year in the 1992 to 2001
able 2. Distribution of GVHD Grades after HCT among Patients
ith Chronic Myeloid Leukemia in Chronic Phase
VHD
Grade
Sibling
1985-1991
(n  237)
Sibling
1992-2001
(n  256)
Unrelated
1992-2001
(n  153)
0 113 (48)* 70 (27) 16 (10)
I 34 (14) 28 (11) 8 (5)
II 58 (24) 133 (52) 81 (53)
III 28 (12) 20 (8) 45 (29)
IV 4 (2) 5 (2) 3 (2)
Data indicate the numbers (percentages) of patients in each cate-
gory.
able 3. One-Year Survival among Patients with Chronic Myeloid
eukemia in Chronic Phase, According to GVHD Grade
VHD
Grade
Sibling
1985-1991
Sibling
1992-2001
Unrelated
1992-2001
0 89 (84-95)* 88 (81-96) 75 (84-95)
I 88 (77-99)† 96 (89-99)† 100
II 79 (68-90) 96 (93-99)† 89 (82-96)
III 76 (62-91) 65 (46-85) 67 (53-80)
IV 0 0 0
Data indicate percentage (95% conﬁdence interval) life-table sur-
vival at 1 year after the transplantation.
The calculated upper limit of the 95% conﬁdence interval ex-
ceeded 100%.
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Bohort, compared with 86% (95% CI, 82%-91%) in
he 1985 to 1991 cohort (P  .01; Wald test).
In the 1992 to 2001 cohort, 1-year survival for
ibling recipients who had CML in chronic phase and
rade II GVHD with stage 1 gut involvement but no
kin involvement was 98% (95%CI, 95%-99%), com-
ared with 94% (95% CI, 88%-99%) for those with
rade II GVHD and skin involvement (P  .18; Wald
est). These results demonstrate that the presence or
bsence of skin involvement did not have a statistically
igniﬁcant effect on survival among patients with
rade II GVHD.
ISCUSSION
Our current results indicate that approximately
0% to 70% of patients at our center experience grade
I to IV acute GVHD after HCT from HLA-identical
ibling donors. Approximately 30% of these patients,
r 20% of the total, have stage 1 gastrointestinal
ymptoms in the absence of skin involvement. The
riginal Seattle criteria for staging gut involvement
ncluded the assessment of diarrhea, nausea, and vom-
ting, each evaluated according to a 4-point scale of
everity [1]. In theory, the overall severity of gut in-
olvement was assigned to reﬂect the most severe
ymptom, but in practice, the staging of gut involve-
ent was limited to the assessment of stool volume
ecause of the difﬁculty in applying quantitative scales
or assessment of nausea and vomiting. In fact, the
inimum stool volume proposed in 1974 as indicative
f intestinal GVHD (500 mL/d) greatly exceeds the
ormal upper limit (200 mL/d) in someone who is
ating and represents ﬂorid secretory diarrhea in
omeone who is fasting. Results of a prospective study
ave shown that GVHD is the most common cause of
iarrhea after HCT, even when stool volumes do not
each the 1974 threshold [22].
Resurgent clinical appreciation of upper gastroin-
estinal symptoms as a manifestation of GVHD came
rimarily from 3 studies. In 1986, Spencer et al [23]
eported a prospective study of 50 patients who were
valuated for unexplained nausea and vomiting.
VHD was identiﬁed as the sole cause of symptoms
n 13 cases and a contributory cause together with
nfection in 8 cases. Skin GVHD was present in 16 of
he 21 cases, but stool volume exceeded 500 mL/day
n only 2 cases. In 1990, Weisdorf et al [24] reported
retrospective review in which upper gastrointestinal
ymptoms were identiﬁed in 62 of 469 cases of
VHD. In this series, the presentation of upper gas-
rointestinal symptoms was always accompanied by
VHD in other organs. In 25 cases, upper gastroin-
estinal GVHD presented with rash involving 50%
f the body surface as the only other manifestation of
VHD. In 1998, Wu et al [25] reported a prospective a
B&MTtudy of 76 patients who had 78 episodes of persistent
ausea and anorexia after marrow transplantation.
VHD was identiﬁed as the sole cause of symptoms
n 63 cases (81%). It is important to note that 39 of the
3 cases had no other manifestations of GVHD, sim-
lar to ﬁndings in our study.
The ﬁndings of the present study could be ex-
lained by a true increase in the incidence of GVHD
r by an increase in sensitivity for making the diag-
osis across time. For this reason, we have carefully
onsidered changes in population characteristics and
reatment as possible explanations for a change in the
ncidence of GVHD. Characteristics of the 1985 to
991 and 1992 to 2001 cohorts of patients with HLA-
dentical siblings donors differed in patient age, the
se of TBI in the conditioning regimen, and the
ource of cells used for the transplant. Patients in the
992 to 2001 cohort were older than those in the 1985
o 1991 cohort, but multivariate analysis showed that
his difference did not account for the higher inci-
ence of GVHD in the 1992 to 2001 cohort (data not
hown). The decreased use of TBI in the 1992 to 2001
ohort is not likely to account for the increased inci-
ence of GVHD, because higher-dose TBI regimens
ave been associated with an increased incidence of
VHD [21]. Finally, results of randomized trials have
hown that the incidence of acute GVHD is at most
nly slightly increased by the use of mobilized blood
s opposed to marrow [26,27]. Hence, the differences
etween the 1985 to 1991 and 1992 to 2001 cohorts
re not likely to account for the increased incidence of
VHD across time.
During the early 1990s, 3 major changes in clinical
ractice that could have affected the incidence of
VHD were made at our center. The use of laminar
irﬂow isolation was abandoned, the use of ganciclovir
or preemptive treatment of CMV infection was be-
un, and prophylactic administration of ﬂuconazole
hroughout the ﬁrst 75 days after the transplant was
ntroduced. Randomized clinical trials showed that
aminar airﬂow isolation reduced the incidence of
cute GVHD among patients with aplastic anemia
20] but not among patients with hematological ma-
ignancies [28], in whom effective gut decontamina-
ion is difﬁcult to achieve [29]. Similarly, a prospective
tudy of ganciclovir administered at the time of en-
raftment in CMV-seropositive recipients showed no
igniﬁcant effect on the incidence of grades II to IV
VHD [14]. A randomized prospective study of pro-
hylactic ﬂuconazole administration showed no sig-
iﬁcant effect on the incidence of grades II to IV
VHD, on the overall distribution of gut stages or on
he incidence of stages 1 to 4 or 2 to 4 gut involvement
17]. The results of these studies suggest that practice
hanges introduced during the early 1990s cannot
ccount for the increased incidence of gut GVHD
cross time at our center.
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3The advent of preemptive therapy for CMV in-
ection has virtually eliminated CMV enteritis as a
ause of gastrointestinal symptoms in our center, and
ost patients with anorexia, nausea, vomiting, or di-
rrhea persisting beyond day 20 after allogeneic HCT
re now diagnosed with acute GVHD [22,25,30-32].
n nearly all cases, the diagnosis is supported by gastric
33], or less often rectal, biopsy, made available
hrough the services of full-time gastroenterology
onsultants dedicated to the management of HCT
ecipients. It is conceivable that gut GVHD has been
verdiagnosed in our center since 1992, but the diag-
osis was conﬁrmed by biopsy in nearly all cases.
ther explanations for nausea, vomiting, and diarrhea
ere generally not apparent when GVHD was diag-
osed, and gastrointestinal symptoms attributed to
VHD have typically resolved after starting glu-
ocorticoid treatment [25]. Given the absence of other
xplanations for changes in the incidence of GVHD,
e believe that isolated gut GVHD was underdiag-
osed in our center before 1991. Reassessment of
hese cases is not possible because gastroenterology
onsultation was not routinely requested for patients
ho had upper gastrointestinal symptoms without di-
rrhea, and biopsy conﬁrmation of the diagnosis is not
vailable.
The experience of our pathologists in reviewing
utside specimens has suggested that gastrointestinal
VHD was also underdiagnosed in other centers dur-
ng the 1980s. The diagnostic sensitivity of histopa-
hology has improved since then, but practices still
ary considerably with respect to the frequency of
astroenterology consultation, the use of endoscopy,
he sites selected for biopsy, the number of biopsies
aken, the processing of samples, and the number of
ections reviewed [33].
Our data suggest that early diagnosis and appro-
riate treatment of upper gastrointestinal GVHD can
ecrease morbidity, although treatment does not af-
ect survival because mortality associated with upper
astrointestinal GVHD is low. We hypothesize that
arlier diagnosis and treatment of gastrointestinal
VHD explains the decreased administration of par-
nteral nutrition after day 21, although improvements
n control of CMV infection during the past decade
ould also have contributed to this effect. The in-
reased incidence of acute GVHD across time in our
enter and the strikingly different incidence rates of
cute GVHD among centers ostensibly using closely
imilar approaches for prophylaxis highlight the need
or considerable caution in the interpretation of pub-
ished GVHD incidence data. Until more robust
ethods for grading acute GVHD are developed, we
ould favor the use of double-blind designs, whenever
easible, for future prospective phase III studies in
hich the incidence of acute GVHD is the primary
utcome of interest. 1
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